Lunai Bioworks signs collaboration agreement with BrainStorm Therapeutics on Parkinson’s disease research
LNAI•Collaboration agreement targets Parkinson’s disease research
Lunai Bioworks signed a Master Collaboration Agreement with BrainStorm Therapeutics focused on precision Parkinson’s disease drug development.
- First collaboration data readout is targeted for the first half of 2027.
- BioSymetrics’ Contingent AI platform will stratify Parkinson’s patients, prioritize biomarkers, and identify therapeutic targets.
- BrainStorm will test hypotheses in patient-derived midbrain organoids and generate translational evidence to support partner-ready programs.
- The strategy targets near-term trial design support, medium-term biomarker panels, and longer-term therapeutic programs for pharma partnering.
